Point mutation of the p53 gene resulting in splicing inhibition in small cell lung carcinoma
Authors:
- Tetsu AkiyamaTATetsu Akiyama
- Naoki MoriNMNaoki Mori
- Hideaki MizoguchiHMHideaki Mizoguchi
- Kumao ToyoshimaKTKumao Toyoshima
- Takashi SugimuraTSTakashi Sugimura
- Masaaki TeradaMTMasaaki Terada
- Jun YokotaJYJun Yokota
- 1 December 1990
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 173 (2) , 697-703
Abstract
No abstract availableKeywords
Funding Information
- Foundation for Promotion of Cancer Research
- Ministry of Education, Culture, Sports, Science and Technology
- Ministry of Health, Labour and Welfare
This publication has 10 references indexed in Scilit:
- Identification of intronic point mutations as an alternative mechanism for p53 inactivation in lung cancer.Journal of Clinical Investigation, 1990
- Role of the retinoblastoma gene in the initiation and progression of human cancer.Journal of Clinical Investigation, 1990
- Oncogenic Point Mutations in the Human Retinoblastoma Gene: Their Application to Genetic CounselingNew England Journal of Medicine, 1989
- Tumor Suppressor Genes: The Puzzle and the PromiseScience, 1989
- Mutations in the p53 gene occur in diverse human tumour typesNature, 1989
- p53: A Frequent Target for Genetic Abnormalities in Lung CancerScience, 1989
- Point Mutational Inactivation of the Retinoblastoma AntioncogeneScience, 1989
- Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells.The EMBO Journal, 1985
- Specific transcription and RNA splicing defects in five cloned β-thalassaemia genesNature, 1983
- Linkage of β-thalassaemia mutations and β-globin gene polymorphisms with DNA polymorphisms in human β-globin gene clusterNature, 1982